Exact Mass: 413.14342280000005

Exact Mass Matches: 413.14342280000005

Found 70 metabolites which its exact mass value is equals to given mass value 413.14342280000005, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

(-)-alpha-Narcotine

(3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-2H,5H,6H,7H,8H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-1,3-dihydro-2-benzofuran-1-one

C22H23NO7 (413.1474448)


(-)-alpha-Narcotine is found in opium poppy. (-)-alpha-Narcotine is an alkaloid from Papaver somniferum (opium poppy).Noscapine (also known as Narcotine, Nectodon, Nospen, and Anarcotine) is a benzylisoquinoline alkaloid from plants of the Papaveraceae family, without significant painkilling properties. This agent is primarily used for its antitussive (cough-suppressing) effects. It has also been shown to have anticancer activity. (Wikipedia). R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants > R05DA - Opium alkaloids and derivatives C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D019141 - Respiratory System Agents > D000996 - Antitussive Agents Alkaloid from Papaver somniferum (opium poppy) D002491 - Central Nervous System Agents

   

Aminodeoxyfutalosine

6-Amino-6-deoxyfutalosine

C19H19N5O6 (413.1335274)


   

13E-Tetranor-16-carboxy-LTE4

(3E,5Z,7E,9E,11R,12S)-11-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}-12-hydroxyhexadeca-3,5,7,9-tetraenedioic acid

C19H27NO7S (413.1508152)


13E-tetranor-16-carboxy-LTE4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 13E-tetranor-16-carboxy-LTE4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078)

   

(±)-alpha-Narcotine

6,7-dimethoxy-3-{4-methoxy-6-methyl-2H,5H,6H,7H,8H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl}-1,3-dihydro-2-benzofuran-1-one

C22H23NO7 (413.1474448)


(±)-alpha-Narcotine is formed in opium, as an artifact. Formed in opium, prob. as an artifact

   

Piperazine, 1-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methyl-

Piperazine, 1-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methyl-

C23H25Cl2N3 (413.142543)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents

   

EGFR Inhibitor

N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide

C21H18F3N5O (413.1463374)


   
   

Oreonone

1-Methoxy-13-oxoallocryptopine

C22H23NO7 (413.1474448)


   
   
   

narcotine

beta-Narcotine

C22H23NO7 (413.1474448)


Origin: Plant; SubCategory_DNP: Isoquinoline alkaloids, Morphine alkaloids

   
   

5-p-hydroxycinnamoyl adenosine|amaricine

5-p-hydroxycinnamoyl adenosine|amaricine

C19H19N5O6 (413.1335274)


   

beta-D-fructofuranosyl-(2->1)-alpha-D-[2-O-L-alanyl]glucopyranoside

beta-D-fructofuranosyl-(2->1)-alpha-D-[2-O-L-alanyl]glucopyranoside

C15H27NO12 (413.1533182)


   

Noscapine

(3S)-3-[(5R)-6-methyl-4-(methyloxy)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6,7-bis(methyloxy)-2-benzofuran-1(3H)-one

C22H23NO7 (413.1474448)


R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants > R05DA - Opium alkaloids and derivatives C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents relative retention time with respect to 9-anthracene Carboxylic Acid is 0.727 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.725 IPB_RECORD: 1361; CONFIDENCE confident structure CONFIDENCE standard compound; EAWAG_UCHEM_ID 3024

   

S,R-Noscapine

S,R-Noscapine

C22H23NO7 (413.1474448)


Acquisition and generation of the data is financially supported by the Max-Planck-Society IPB_RECORD: 2481; CONFIDENCE confident structure

   

6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-2-benzofuran-1-one

NCGC00015757-10!6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-2-benzofuran-1-one

C22H23NO7 (413.1474448)


   
   

Longatin

Noscapine

C22H23NO7 (413.1474448)


R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants > R05DA - Opium alkaloids and derivatives C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent Origin: Plant; SubCategory_DNP: Isoquinoline alkaloids, Morphine alkaloids, Noscapine alkaloids D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents

   
   

Gnoscopine

6,7-dimethoxy-3-{4-methoxy-6-methyl-2H,5H,6H,7H,8H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl}-1,3-dihydro-2-benzofuran-1-one

C22H23NO7 (413.1474448)


   

16-carboxy-Delta(13)-17,18,19,20-tetranor-leukotriene E4

(5Z,7E,9E,11R,12S)-11-(L-cystein-S-yl)-12-hydroxyhexadeca-3,5,7,9-tetraenedioic acid;(5Z,7E,9E,11R,12S)-11-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-12-hydroxyhexadeca-3,5,7,9-tetraenedioic acid

C19H27NO7S (413.1508152)


An icosanoid that is leukotriene E4 in which the isolated double bond has migrated into conjugation with the triene moiety and in which four methylene groups have been lost from the resulting carboxyalkyl chain.

   

2-[[4-[(2-cyanoethyl)ethylamino]phenyl]azo]-5-(phenylazo)thiophene-3-carbonitrile

2-[[4-[(2-cyanoethyl)ethylamino]phenyl]azo]-5-(phenylazo)thiophene-3-carbonitrile

C22H19N7S (413.14225740000006)


   

Obatoclax Mesylate

Obatoclax Mesylate

C21H23N3O4S (413.14091980000006)


D004791 - Enzyme Inhibitors

   

5-chloro-2-[2-[4-[(2-cyanoethyl)methylamino]phenyl]vinyl]-1,3,3-trimethyl-3H-indolium chloride

5-chloro-2-[2-[4-[(2-cyanoethyl)methylamino]phenyl]vinyl]-1,3,3-trimethyl-3H-indolium chloride

C23H25Cl2N3 (413.142543)


   
   

1-[3,5-Bis(trifluoromethyl)phenyl]-3-[(1S,2S)-(+)-2-(dimethylamino)cyclohexyl]thiourea(S,S-TUC)

1-[3,5-Bis(trifluoromethyl)phenyl]-3-[(1S,2S)-(+)-2-(dimethylamino)cyclohexyl]thiourea(S,S-TUC)

C17H21F6N3S (413.1360298000001)


   

4-hydroxy-alpha-[[[3-(4-methoxyphenyl)-1-methylpropyl]amino]methyl]-3-(methylsulphinyl)benzyl alcohol hydrochloride

4-hydroxy-alpha-[[[3-(4-methoxyphenyl)-1-methylpropyl]amino]methyl]-3-(methylsulphinyl)benzyl alcohol hydrochloride

C20H28ClNO4S (413.1427478000001)


   

1-[3,5-Bis(trifluoromethyl)phenyl]-3-[(1R,2R)-(-)-2-(dimethylamino)cyclohexyl]thiourea(R,R-TUC)

1-[3,5-Bis(trifluoromethyl)phenyl]-3-[(1R,2R)-(-)-2-(dimethylamino)cyclohexyl]thiourea(R,R-TUC)

C17H21F6N3S (413.1360298000001)


   

Aurora Kinase Inhibitor III

Aurora Kinase Inhibitor III

C21H18F3N5O (413.1463374)


   
   

4-[benzyl(propan-2-yl)sulfamoyl]-N-(5-methyl-1,2-oxazol-3-yl)benzamide

4-[benzyl(propan-2-yl)sulfamoyl]-N-(5-methyl-1,2-oxazol-3-yl)benzamide

C21H23N3O4S (413.14091980000006)


   

(3r)-3-Cyclopentyl-7-[(4-Methylpiperazin-1-Yl)sulfonyl]-3,4-Dihydro-2h-1,2-Benzothiazine 1,1-Dioxide

(3r)-3-Cyclopentyl-7-[(4-Methylpiperazin-1-Yl)sulfonyl]-3,4-Dihydro-2h-1,2-Benzothiazine 1,1-Dioxide

C18H27N3O4S2 (413.1442902)


   

Delta(13)-16-carboxy-tetranor-LTE4

Delta(13)-16-carboxy-tetranor-LTE4

C19H27NO7S (413.1508152)


   

6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-isobenzofuran-1-one

6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-isobenzofuran-1-one

C22H23NO7 (413.1474448)


   

3-(2,5-dioxo-1-pyrrolidinyl)-N-(1-ethyl-2-oxo-6-benzo[cd]indolyl)benzamide

3-(2,5-dioxo-1-pyrrolidinyl)-N-(1-ethyl-2-oxo-6-benzo[cd]indolyl)benzamide

C24H19N3O4 (413.13754940000007)


   

6-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-3,4-dihydro-1H-quinolin-2-one

6-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-3,4-dihydro-1H-quinolin-2-one

C21H23N3O4S (413.14091980000006)


   

N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[[5-(3-methylphenyl)-1,3,4-oxadiazol-2-yl]thio]acetamide

N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[[5-(3-methylphenyl)-1,3,4-oxadiazol-2-yl]thio]acetamide

C21H23N3O4S (413.14091980000006)


   

6-Cyano-1-(2-methylphenyl)-7-(4-methylphenyl)-5-oxo-[1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylic acid ethyl ester

6-Cyano-1-(2-methylphenyl)-7-(4-methylphenyl)-5-oxo-[1,2,4]triazolo[4,3-a]pyrimidine-3-carboxylic acid ethyl ester

C23H19N5O3 (413.1487824000001)


   

(3S)-6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one

(3S)-6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one

C22H23NO7 (413.1474448)


   

N-(1,3-benzodioxol-5-ylmethyl)-6-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-quinazolinamine

N-(1,3-benzodioxol-5-ylmethyl)-6-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-quinazolinamine

C24H19N3O4 (413.13754940000007)


   

4-[4-[(2S,3S,4S)-2-cyano-4-(hydroxymethyl)-1-methylsulfonyl-3-azetidinyl]phenyl]-N,N-dimethylbenzamide

4-[4-[(2S,3S,4S)-2-cyano-4-(hydroxymethyl)-1-methylsulfonyl-3-azetidinyl]phenyl]-N,N-dimethylbenzamide

C21H23N3O4S (413.14091980000006)


   

4-[4-[(2S,3R,4R)-2-cyano-4-(hydroxymethyl)-1-methylsulfonyl-3-azetidinyl]phenyl]-N,N-dimethylbenzamide

4-[4-[(2S,3R,4R)-2-cyano-4-(hydroxymethyl)-1-methylsulfonyl-3-azetidinyl]phenyl]-N,N-dimethylbenzamide

C21H23N3O4S (413.14091980000006)


   

4-[4-[(2R,3S,4S)-2-cyano-4-(hydroxymethyl)-1-methylsulfonylazetidin-3-yl]phenyl]-N,N-dimethylbenzamide

4-[4-[(2R,3S,4S)-2-cyano-4-(hydroxymethyl)-1-methylsulfonylazetidin-3-yl]phenyl]-N,N-dimethylbenzamide

C21H23N3O4S (413.14091980000006)


   

4-[4-[(2R,3R,4R)-2-cyano-4-(hydroxymethyl)-1-methylsulfonyl-3-azetidinyl]phenyl]-N,N-dimethylbenzamide

4-[4-[(2R,3R,4R)-2-cyano-4-(hydroxymethyl)-1-methylsulfonyl-3-azetidinyl]phenyl]-N,N-dimethylbenzamide

C21H23N3O4S (413.14091980000006)


   

4-[4-[(2R,3S,4R)-2-cyano-4-(hydroxymethyl)-1-methylsulfonyl-3-azetidinyl]phenyl]-N,N-dimethylbenzamide

4-[4-[(2R,3S,4R)-2-cyano-4-(hydroxymethyl)-1-methylsulfonyl-3-azetidinyl]phenyl]-N,N-dimethylbenzamide

C21H23N3O4S (413.14091980000006)


   

4-[4-[(2S,3S,4R)-2-cyano-4-(hydroxymethyl)-1-methylsulfonyl-3-azetidinyl]phenyl]-N,N-dimethylbenzamide

4-[4-[(2S,3S,4R)-2-cyano-4-(hydroxymethyl)-1-methylsulfonyl-3-azetidinyl]phenyl]-N,N-dimethylbenzamide

C21H23N3O4S (413.14091980000006)


   

2-Amino-3-[(2-hexanoyloxy-3-propanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid

2-Amino-3-[(2-hexanoyloxy-3-propanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid

C15H28NO10P (413.14507580000003)


   

2-Amino-3-[(3-butanoyloxy-2-pentanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid

2-Amino-3-[(3-butanoyloxy-2-pentanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid

C15H28NO10P (413.14507580000003)


   

3-[(3-Acetyloxy-2-heptanoyloxypropoxy)-hydroxyphosphoryl]oxy-2-aminopropanoic acid

3-[(3-Acetyloxy-2-heptanoyloxypropoxy)-hydroxyphosphoryl]oxy-2-aminopropanoic acid

C15H28NO10P (413.14507580000003)


   
   

(13E)-16-carboxy-Delta(13)-17,18,19,20-tetranor-leukotriene E4

(13E)-16-carboxy-Delta(13)-17,18,19,20-tetranor-leukotriene E4

C19H27NO7S (413.1508152)


A 16-carboxy-Delta(13)-17,18,19,20-tetranor-leukotriene E4 in which the double bond at position 13-14 has E-configuration.

   

(-)-noscapine

(-)-noscapine

C22H23NO7 (413.1474448)


A benzylisoquinoline alkaloid that is 1,2,3,4-tetrahydroisoquinoline which is substituted by a 4,5-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-1-yl group at position 1, a methylenedioxy group at positions 6-7 and a methoxy group at position 8. Obtained from plants of the Papaveraceae family, it lacks significant painkilling properties and is primarily used for its antitussive (cough-suppressing) effects.

   

HLI373 (dihydrochloride)

HLI373 (dihydrochloride)

C18H25Cl2N5O2 (413.138521)


HLI373 dihydrochloride is an efficacious Hdm2 inhibitor. HLI373 dihydrochloride inhibits the ubiquitin ligase activity of Hdm2. HLI373 dihydrochloride is effective in inducing apoptosis of several tumor cells that are sensitive to DNA-damaging agents[1]. Antimalarial activity[2].

   

(5s,8s,9r)-8-benzoyl-2-[(2s,3r)-3-[(1z)-but-1-en-1-yl]oxiran-2-yl]-6,9-dihydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]nona-2,6-dien-4-one

(5s,8s,9r)-8-benzoyl-2-[(2s,3r)-3-[(1z)-but-1-en-1-yl]oxiran-2-yl]-6,9-dihydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]nona-2,6-dien-4-one

C22H23NO7 (413.1474448)


   

(2r,3r,4s,5s,6r)-2-{[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl (2s)-2-aminopropanoate

(2r,3r,4s,5s,6r)-2-{[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl (2s)-2-aminopropanoate

C15H27NO12 (413.1533182)